Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H24N2OS |
| Molecular Weight | 340.482 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C2=CC=CC=C2
InChI
InChIKey=RSUVYMGADVXGOU-BUHFOSPRSA-N
InChI=1S/C20H24N2OS/c1-22(2)15-8-16-24-19-12-7-6-11-18(19)21-20(23)14-13-17-9-4-3-5-10-17/h3-7,9-14H,8,15-16H2,1-2H3,(H,21,23)/b14-13+
| Molecular Formula | C20H24N2OS |
| Molecular Weight | 340.482 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Cinanserin is a 5-hydroxytryptamine receptor antagonist; it shows a low affinity to 5-HT2b binding sites and a 4-to 10-fold lower affinity to 5-HT2c receptor binding sites than for 5-HT2a sites. Nevertheless, at concentrations normally used 5-HT2c receptor blocking effects are still likely. Experiments on animal have shown that intravenous administration of cinanserin significantly reduces systemic burn edema and leukocyte-endothelial interactions.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2096662 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14248340 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Molecular serotonergic mechanisms appear to mediate genetic sensitivity to cocaine-induced convulsions. | 2000-04-28 |
|
| The role of serotonin(2) receptors in mediating cocaine-induced convulsions. | 2000-04 |
|
| Cocaine-induced convulsions: pharmacological antagonism at serotonergic, muscarinic and sigma receptors. | 1997-02 |
|
| p,p'-DDT-induced myoclonus in mice: the effect of enhanced 5-HT neurotransmission. | 1985-02 |
|
| Differentiaton of neuropharmacological actions of apomorphine and d-amphetamine. | 1976-12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23523219
in rats: bolus (5 mg/kg body weight)
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15890949
Binding of both cinanserin and its hydrochloride to bacterially expressed 3C-like proteinase (3CLpro) of syndrome-associated coronavirus (SARS-CoV) and the related human coronavirus 229E (HCoV-229E) was demonstrated by surface plasmon resonance technology. The antiviral activity of cinanserin was further evaluated in tissue culture assays, namely, a replicon system based on HCoV-229E and quantitative test assays with infectious SARS-CoV and HCoV-229E. The level of virus RNA and infectious particles was reduced by up to 4 log units, with IC50 values ranging from 19 to 34 microM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:26 GMT 2025
by
admin
on
Mon Mar 31 18:22:26 GMT 2025
|
| Record UNII |
KI6J9OY7A3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5475158
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
CINANSERIN
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
2185
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
1166-34-3
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
KI6J9OY7A3
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL18786
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
C83624
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
145999
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
100000081059
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
DTXSID7045653
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
SUB06285MIG
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |